Hevylite in IMWG Guidelines for the First Time!
The latest IMWG criteria for response and minimal residual disease (MRD) assessment in multiple myeloma was published today/earlier this week. These guidelines seek to collate the most progressive and effective clinical recommendations from various key opinion leaders and publications.
The IMWG now acknowledges the benefits of using Hevylite for monitoring oligosecretory multiple myeloma and for overcoming “limitations associated with monitoring β-migrating monoclonal IgA by electrophoresis”. Assessment of Hevylite ratios may play “an important role in the definition of a minimal residual disease-negative state”.
“In some cases… heavy/light chain ratios provided additional sensitivity [to conventional methods]”
Freelite is recommended by name and should be performed for all patients at suspected complete response (CR) or progression. A normal sFLC ratio is required to define a stringent CR. These new guidelines follow the inclusion of Freelite in the revised definition of multiple myeloma.
“All recommendations regarding clinical uses relating to serum FLC levels or FLC ratio are based on results obtained with the validated Freelite test (Binding Site, Birmingham, UK).”
The paper is available to order here